nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisoprolol—CYP2D6—breast cancer	0.195	0.538	CbGaD
Bisoprolol—CYP3A4—breast cancer	0.168	0.462	CbGaD
Bisoprolol—CYP3A4—Exemestane—breast cancer	0.0385	0.103	CbGbCtD
Bisoprolol—CYP2D6—Idarubicin—breast cancer	0.0347	0.093	CbGbCtD
Bisoprolol—CYP3A4—Letrozole—breast cancer	0.0327	0.0876	CbGbCtD
Bisoprolol—CYP3A4—Anastrozole—breast cancer	0.0291	0.0781	CbGbCtD
Bisoprolol—CYP3A4—Toremifene—breast cancer	0.0267	0.0714	CbGbCtD
Bisoprolol—CYP3A4—Fulvestrant—breast cancer	0.0248	0.0664	CbGbCtD
Bisoprolol—CYP3A4—Thiotepa—breast cancer	0.0221	0.0592	CbGbCtD
Bisoprolol—CYP3A4—Ixabepilone—breast cancer	0.0202	0.0541	CbGbCtD
Bisoprolol—CYP3A4—Lapatinib—breast cancer	0.0194	0.0521	CbGbCtD
Bisoprolol—CYP2D6—Vinorelbine—breast cancer	0.017	0.0454	CbGbCtD
Bisoprolol—CYP2D6—Tamoxifen—breast cancer	0.0153	0.041	CbGbCtD
Bisoprolol—CYP3A4—Raloxifene—breast cancer	0.0147	0.0395	CbGbCtD
Bisoprolol—CYP3A4—Vinorelbine—breast cancer	0.0108	0.0289	CbGbCtD
Bisoprolol—CYP2D6—Vinblastine—breast cancer	0.0105	0.028	CbGbCtD
Bisoprolol—CYP3A4—Tamoxifen—breast cancer	0.00974	0.0261	CbGbCtD
Bisoprolol—CYP3A4—Mitoxantrone—breast cancer	0.0095	0.0254	CbGbCtD
Bisoprolol—CYP3A4—Paclitaxel—breast cancer	0.00758	0.0203	CbGbCtD
Bisoprolol—CYP3A4—Irinotecan—breast cancer	0.00748	0.02	CbGbCtD
Bisoprolol—CYP3A4—Vinblastine—breast cancer	0.00665	0.0178	CbGbCtD
Bisoprolol—CYP2D6—Doxorubicin—breast cancer	0.00642	0.0172	CbGbCtD
Bisoprolol—CYP3A4—Docetaxel—breast cancer	0.00548	0.0147	CbGbCtD
Bisoprolol—CYP3A4—Doxorubicin—breast cancer	0.00408	0.0109	CbGbCtD
Bisoprolol—Chlorphenesin—CYP19A1—breast cancer	0.000409	0.13	CrCbGaD
Bisoprolol—Chlorphenesin—BCHE—breast cancer	0.000408	0.13	CrCbGaD
Bisoprolol—Betaxolol—CYP2D6—breast cancer	0.000226	0.0721	CrCbGaD
Bisoprolol—Acebutolol—CYP2D6—breast cancer	0.000207	0.0659	CrCbGaD
Bisoprolol—Oxprenolol—CYP2D6—breast cancer	0.000205	0.0654	CrCbGaD
Bisoprolol—Chlorphenesin—CYP3A4—breast cancer	0.000192	0.0613	CrCbGaD
Bisoprolol—Chlorphenesin—PTGS2—breast cancer	0.000188	0.06	CrCbGaD
Bisoprolol—Alprenolol—CYP2D6—breast cancer	0.000188	0.0598	CrCbGaD
Bisoprolol—Metoprolol—CYP2D6—breast cancer	0.000175	0.0556	CrCbGaD
Bisoprolol—Pindolol—CYP2D6—breast cancer	0.000161	0.0515	CrCbGaD
Bisoprolol—Atenolol—ABCB1—breast cancer	0.00016	0.051	CrCbGaD
Bisoprolol—Acebutolol—ABCB1—breast cancer	0.000148	0.0471	CrCbGaD
Bisoprolol—Metoprolol—ABCB1—breast cancer	0.000125	0.0397	CrCbGaD
Bisoprolol—Propranolol—CYP1A1—breast cancer	0.000118	0.0377	CrCbGaD
Bisoprolol—Propranolol—CYP2D6—breast cancer	8.81e-05	0.0281	CrCbGaD
Bisoprolol—Propranolol—CYP3A4—breast cancer	7.56e-05	0.0241	CrCbGaD
Bisoprolol—Propranolol—ABCB1—breast cancer	6.29e-05	0.0201	CrCbGaD
Bisoprolol—Headache—Mitoxantrone—breast cancer	3.87e-05	0.000171	CcSEcCtD
Bisoprolol—Hypotension—Capecitabine—breast cancer	3.87e-05	0.000171	CcSEcCtD
Bisoprolol—Insomnia—Docetaxel—breast cancer	3.87e-05	0.000171	CcSEcCtD
Bisoprolol—Paraesthesia—Docetaxel—breast cancer	3.84e-05	0.00017	CcSEcCtD
Bisoprolol—Alopecia—Methotrexate—breast cancer	3.83e-05	0.000169	CcSEcCtD
Bisoprolol—Vomiting—Gemcitabine—breast cancer	3.83e-05	0.000169	CcSEcCtD
Bisoprolol—Bradycardia—Doxorubicin—breast cancer	3.82e-05	0.000169	CcSEcCtD
Bisoprolol—Dyspnoea—Docetaxel—breast cancer	3.81e-05	0.000169	CcSEcCtD
Bisoprolol—Somnolence—Docetaxel—breast cancer	3.8e-05	0.000168	CcSEcCtD
Bisoprolol—Mental disorder—Methotrexate—breast cancer	3.8e-05	0.000168	CcSEcCtD
Bisoprolol—Rash—Gemcitabine—breast cancer	3.8e-05	0.000168	CcSEcCtD
Bisoprolol—Dermatitis—Gemcitabine—breast cancer	3.79e-05	0.000168	CcSEcCtD
Bisoprolol—Eye disorder—Epirubicin—breast cancer	3.79e-05	0.000168	CcSEcCtD
Bisoprolol—Tinnitus—Epirubicin—breast cancer	3.78e-05	0.000167	CcSEcCtD
Bisoprolol—Erythema—Methotrexate—breast cancer	3.78e-05	0.000167	CcSEcCtD
Bisoprolol—Headache—Gemcitabine—breast cancer	3.77e-05	0.000167	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Capecitabine—breast cancer	3.77e-05	0.000167	CcSEcCtD
Bisoprolol—Cardiac disorder—Epirubicin—breast cancer	3.77e-05	0.000167	CcSEcCtD
Bisoprolol—Flushing—Epirubicin—breast cancer	3.77e-05	0.000167	CcSEcCtD
Bisoprolol—Vomiting—Fluorouracil—breast cancer	3.77e-05	0.000167	CcSEcCtD
Bisoprolol—Rhinitis—Doxorubicin—breast cancer	3.76e-05	0.000167	CcSEcCtD
Bisoprolol—Dyspepsia—Docetaxel—breast cancer	3.76e-05	0.000166	CcSEcCtD
Bisoprolol—Hepatitis—Doxorubicin—breast cancer	3.76e-05	0.000166	CcSEcCtD
Bisoprolol—Insomnia—Capecitabine—breast cancer	3.74e-05	0.000166	CcSEcCtD
Bisoprolol—Hypoaesthesia—Doxorubicin—breast cancer	3.74e-05	0.000165	CcSEcCtD
Bisoprolol—Rash—Fluorouracil—breast cancer	3.73e-05	0.000165	CcSEcCtD
Bisoprolol—Dermatitis—Fluorouracil—breast cancer	3.73e-05	0.000165	CcSEcCtD
Bisoprolol—Pharyngitis—Doxorubicin—breast cancer	3.73e-05	0.000165	CcSEcCtD
Bisoprolol—Paraesthesia—Capecitabine—breast cancer	3.72e-05	0.000164	CcSEcCtD
Bisoprolol—Hypersensitivity—Paclitaxel—breast cancer	3.72e-05	0.000164	CcSEcCtD
Bisoprolol—Headache—Fluorouracil—breast cancer	3.71e-05	0.000164	CcSEcCtD
Bisoprolol—Oedema peripheral—Doxorubicin—breast cancer	3.7e-05	0.000164	CcSEcCtD
Bisoprolol—Dysgeusia—Methotrexate—breast cancer	3.7e-05	0.000164	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Docetaxel—breast cancer	3.69e-05	0.000163	CcSEcCtD
Bisoprolol—Connective tissue disorder—Doxorubicin—breast cancer	3.69e-05	0.000163	CcSEcCtD
Bisoprolol—Dyspnoea—Capecitabine—breast cancer	3.69e-05	0.000163	CcSEcCtD
Bisoprolol—Fatigue—Docetaxel—breast cancer	3.69e-05	0.000163	CcSEcCtD
Bisoprolol—Angiopathy—Epirubicin—breast cancer	3.68e-05	0.000163	CcSEcCtD
Bisoprolol—Nausea—Mitoxantrone—breast cancer	3.67e-05	0.000162	CcSEcCtD
Bisoprolol—Nausea—Irinotecan—breast cancer	3.67e-05	0.000162	CcSEcCtD
Bisoprolol—Mediastinal disorder—Epirubicin—breast cancer	3.66e-05	0.000162	CcSEcCtD
Bisoprolol—Pain—Docetaxel—breast cancer	3.66e-05	0.000162	CcSEcCtD
Bisoprolol—Constipation—Docetaxel—breast cancer	3.66e-05	0.000162	CcSEcCtD
Bisoprolol—Back pain—Methotrexate—breast cancer	3.65e-05	0.000162	CcSEcCtD
Bisoprolol—Dyspepsia—Capecitabine—breast cancer	3.64e-05	0.000161	CcSEcCtD
Bisoprolol—Arrhythmia—Epirubicin—breast cancer	3.63e-05	0.00016	CcSEcCtD
Bisoprolol—Visual impairment—Doxorubicin—breast cancer	3.62e-05	0.00016	CcSEcCtD
Bisoprolol—Asthenia—Paclitaxel—breast cancer	3.62e-05	0.00016	CcSEcCtD
Bisoprolol—Alopecia—Epirubicin—breast cancer	3.59e-05	0.000159	CcSEcCtD
Bisoprolol—Nausea—Gemcitabine—breast cancer	3.58e-05	0.000158	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Capecitabine—breast cancer	3.57e-05	0.000158	CcSEcCtD
Bisoprolol—Fatigue—Capecitabine—breast cancer	3.57e-05	0.000158	CcSEcCtD
Bisoprolol—Pruritus—Paclitaxel—breast cancer	3.57e-05	0.000158	CcSEcCtD
Bisoprolol—Mental disorder—Epirubicin—breast cancer	3.56e-05	0.000157	CcSEcCtD
Bisoprolol—Pain—Capecitabine—breast cancer	3.54e-05	0.000157	CcSEcCtD
Bisoprolol—Constipation—Capecitabine—breast cancer	3.54e-05	0.000157	CcSEcCtD
Bisoprolol—Erythema—Epirubicin—breast cancer	3.53e-05	0.000156	CcSEcCtD
Bisoprolol—Feeling abnormal—Docetaxel—breast cancer	3.52e-05	0.000156	CcSEcCtD
Bisoprolol—Nausea—Fluorouracil—breast cancer	3.52e-05	0.000156	CcSEcCtD
Bisoprolol—Eye disorder—Doxorubicin—breast cancer	3.51e-05	0.000155	CcSEcCtD
Bisoprolol—Ill-defined disorder—Methotrexate—breast cancer	3.5e-05	0.000155	CcSEcCtD
Bisoprolol—Tinnitus—Doxorubicin—breast cancer	3.5e-05	0.000155	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Docetaxel—breast cancer	3.5e-05	0.000155	CcSEcCtD
Bisoprolol—Cardiac disorder—Doxorubicin—breast cancer	3.49e-05	0.000154	CcSEcCtD
Bisoprolol—Flushing—Doxorubicin—breast cancer	3.49e-05	0.000154	CcSEcCtD
Bisoprolol—Dysgeusia—Epirubicin—breast cancer	3.46e-05	0.000153	CcSEcCtD
Bisoprolol—Diarrhoea—Paclitaxel—breast cancer	3.45e-05	0.000153	CcSEcCtD
Bisoprolol—Back pain—Epirubicin—breast cancer	3.42e-05	0.000151	CcSEcCtD
Bisoprolol—Feeling abnormal—Capecitabine—breast cancer	3.41e-05	0.000151	CcSEcCtD
Bisoprolol—Angiopathy—Doxorubicin—breast cancer	3.41e-05	0.000151	CcSEcCtD
Bisoprolol—Malaise—Methotrexate—breast cancer	3.4e-05	0.000151	CcSEcCtD
Bisoprolol—Muscle spasms—Epirubicin—breast cancer	3.4e-05	0.00015	CcSEcCtD
Bisoprolol—Vertigo—Methotrexate—breast cancer	3.39e-05	0.00015	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Capecitabine—breast cancer	3.38e-05	0.00015	CcSEcCtD
Bisoprolol—Mediastinal disorder—Doxorubicin—breast cancer	3.38e-05	0.00015	CcSEcCtD
Bisoprolol—Abdominal pain—Docetaxel—breast cancer	3.38e-05	0.000149	CcSEcCtD
Bisoprolol—Body temperature increased—Docetaxel—breast cancer	3.38e-05	0.000149	CcSEcCtD
Bisoprolol—Arrhythmia—Doxorubicin—breast cancer	3.35e-05	0.000148	CcSEcCtD
Bisoprolol—Dizziness—Paclitaxel—breast cancer	3.34e-05	0.000148	CcSEcCtD
Bisoprolol—Alopecia—Doxorubicin—breast cancer	3.32e-05	0.000147	CcSEcCtD
Bisoprolol—Cough—Methotrexate—breast cancer	3.29e-05	0.000146	CcSEcCtD
Bisoprolol—Mental disorder—Doxorubicin—breast cancer	3.29e-05	0.000146	CcSEcCtD
Bisoprolol—Urticaria—Capecitabine—breast cancer	3.29e-05	0.000145	CcSEcCtD
Bisoprolol—Ill-defined disorder—Epirubicin—breast cancer	3.28e-05	0.000145	CcSEcCtD
Bisoprolol—Body temperature increased—Capecitabine—breast cancer	3.27e-05	0.000145	CcSEcCtD
Bisoprolol—Abdominal pain—Capecitabine—breast cancer	3.27e-05	0.000145	CcSEcCtD
Bisoprolol—Erythema—Doxorubicin—breast cancer	3.27e-05	0.000145	CcSEcCtD
Bisoprolol—Agitation—Epirubicin—breast cancer	3.25e-05	0.000144	CcSEcCtD
Bisoprolol—Chest pain—Methotrexate—breast cancer	3.21e-05	0.000142	CcSEcCtD
Bisoprolol—Arthralgia—Methotrexate—breast cancer	3.21e-05	0.000142	CcSEcCtD
Bisoprolol—Myalgia—Methotrexate—breast cancer	3.21e-05	0.000142	CcSEcCtD
Bisoprolol—Vomiting—Paclitaxel—breast cancer	3.21e-05	0.000142	CcSEcCtD
Bisoprolol—Dysgeusia—Doxorubicin—breast cancer	3.2e-05	0.000142	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	3.19e-05	0.000141	CcSEcCtD
Bisoprolol—Malaise—Epirubicin—breast cancer	3.19e-05	0.000141	CcSEcCtD
Bisoprolol—Rash—Paclitaxel—breast cancer	3.18e-05	0.000141	CcSEcCtD
Bisoprolol—Dermatitis—Paclitaxel—breast cancer	3.18e-05	0.000141	CcSEcCtD
Bisoprolol—Discomfort—Methotrexate—breast cancer	3.18e-05	0.00014	CcSEcCtD
Bisoprolol—Vertigo—Epirubicin—breast cancer	3.17e-05	0.00014	CcSEcCtD
Bisoprolol—Syncope—Epirubicin—breast cancer	3.17e-05	0.00014	CcSEcCtD
Bisoprolol—Back pain—Doxorubicin—breast cancer	3.16e-05	0.00014	CcSEcCtD
Bisoprolol—Headache—Paclitaxel—breast cancer	3.16e-05	0.00014	CcSEcCtD
Bisoprolol—Hypersensitivity—Docetaxel—breast cancer	3.15e-05	0.000139	CcSEcCtD
Bisoprolol—Muscle spasms—Doxorubicin—breast cancer	3.14e-05	0.000139	CcSEcCtD
Bisoprolol—Palpitations—Epirubicin—breast cancer	3.12e-05	0.000138	CcSEcCtD
Bisoprolol—Confusional state—Methotrexate—breast cancer	3.11e-05	0.000137	CcSEcCtD
Bisoprolol—Loss of consciousness—Epirubicin—breast cancer	3.11e-05	0.000137	CcSEcCtD
Bisoprolol—Cough—Epirubicin—breast cancer	3.08e-05	0.000136	CcSEcCtD
Bisoprolol—Asthenia—Docetaxel—breast cancer	3.07e-05	0.000136	CcSEcCtD
Bisoprolol—Infection—Methotrexate—breast cancer	3.06e-05	0.000135	CcSEcCtD
Bisoprolol—Hypersensitivity—Capecitabine—breast cancer	3.05e-05	0.000135	CcSEcCtD
Bisoprolol—Ill-defined disorder—Doxorubicin—breast cancer	3.03e-05	0.000134	CcSEcCtD
Bisoprolol—Pruritus—Docetaxel—breast cancer	3.02e-05	0.000134	CcSEcCtD
Bisoprolol—Nervous system disorder—Methotrexate—breast cancer	3.02e-05	0.000134	CcSEcCtD
Bisoprolol—Thrombocytopenia—Methotrexate—breast cancer	3.02e-05	0.000133	CcSEcCtD
Bisoprolol—Chest pain—Epirubicin—breast cancer	3.01e-05	0.000133	CcSEcCtD
Bisoprolol—Myalgia—Epirubicin—breast cancer	3.01e-05	0.000133	CcSEcCtD
Bisoprolol—Arthralgia—Epirubicin—breast cancer	3.01e-05	0.000133	CcSEcCtD
Bisoprolol—Agitation—Doxorubicin—breast cancer	3e-05	0.000133	CcSEcCtD
Bisoprolol—Anxiety—Epirubicin—breast cancer	3e-05	0.000133	CcSEcCtD
Bisoprolol—Nausea—Paclitaxel—breast cancer	3e-05	0.000132	CcSEcCtD
Bisoprolol—Skin disorder—Methotrexate—breast cancer	2.99e-05	0.000132	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.99e-05	0.000132	CcSEcCtD
Bisoprolol—Hyperhidrosis—Methotrexate—breast cancer	2.98e-05	0.000132	CcSEcCtD
Bisoprolol—Discomfort—Epirubicin—breast cancer	2.97e-05	0.000131	CcSEcCtD
Bisoprolol—Asthenia—Capecitabine—breast cancer	2.97e-05	0.000131	CcSEcCtD
Bisoprolol—Malaise—Doxorubicin—breast cancer	2.95e-05	0.00013	CcSEcCtD
Bisoprolol—Dry mouth—Epirubicin—breast cancer	2.94e-05	0.00013	CcSEcCtD
Bisoprolol—Vertigo—Doxorubicin—breast cancer	2.94e-05	0.00013	CcSEcCtD
Bisoprolol—Syncope—Doxorubicin—breast cancer	2.93e-05	0.00013	CcSEcCtD
Bisoprolol—Pruritus—Capecitabine—breast cancer	2.93e-05	0.00013	CcSEcCtD
Bisoprolol—Diarrhoea—Docetaxel—breast cancer	2.92e-05	0.000129	CcSEcCtD
Bisoprolol—Confusional state—Epirubicin—breast cancer	2.91e-05	0.000129	CcSEcCtD
Bisoprolol—Palpitations—Doxorubicin—breast cancer	2.89e-05	0.000128	CcSEcCtD
Bisoprolol—Oedema—Epirubicin—breast cancer	2.88e-05	0.000128	CcSEcCtD
Bisoprolol—Hypotension—Methotrexate—breast cancer	2.88e-05	0.000127	CcSEcCtD
Bisoprolol—Loss of consciousness—Doxorubicin—breast cancer	2.87e-05	0.000127	CcSEcCtD
Bisoprolol—Infection—Epirubicin—breast cancer	2.86e-05	0.000127	CcSEcCtD
Bisoprolol—Cough—Doxorubicin—breast cancer	2.85e-05	0.000126	CcSEcCtD
Bisoprolol—Shock—Epirubicin—breast cancer	2.84e-05	0.000125	CcSEcCtD
Bisoprolol—Diarrhoea—Capecitabine—breast cancer	2.83e-05	0.000125	CcSEcCtD
Bisoprolol—Nervous system disorder—Epirubicin—breast cancer	2.83e-05	0.000125	CcSEcCtD
Bisoprolol—Dizziness—Docetaxel—breast cancer	2.83e-05	0.000125	CcSEcCtD
Bisoprolol—Thrombocytopenia—Epirubicin—breast cancer	2.82e-05	0.000125	CcSEcCtD
Bisoprolol—Tachycardia—Epirubicin—breast cancer	2.81e-05	0.000124	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Methotrexate—breast cancer	2.81e-05	0.000124	CcSEcCtD
Bisoprolol—Skin disorder—Epirubicin—breast cancer	2.8e-05	0.000124	CcSEcCtD
Bisoprolol—Hyperhidrosis—Epirubicin—breast cancer	2.79e-05	0.000123	CcSEcCtD
Bisoprolol—Insomnia—Methotrexate—breast cancer	2.79e-05	0.000123	CcSEcCtD
Bisoprolol—Myalgia—Doxorubicin—breast cancer	2.78e-05	0.000123	CcSEcCtD
Bisoprolol—Chest pain—Doxorubicin—breast cancer	2.78e-05	0.000123	CcSEcCtD
Bisoprolol—Arthralgia—Doxorubicin—breast cancer	2.78e-05	0.000123	CcSEcCtD
Bisoprolol—Anxiety—Doxorubicin—breast cancer	2.77e-05	0.000123	CcSEcCtD
Bisoprolol—Paraesthesia—Methotrexate—breast cancer	2.77e-05	0.000122	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	2.76e-05	0.000122	CcSEcCtD
Bisoprolol—Discomfort—Doxorubicin—breast cancer	2.75e-05	0.000122	CcSEcCtD
Bisoprolol—Dyspnoea—Methotrexate—breast cancer	2.75e-05	0.000121	CcSEcCtD
Bisoprolol—Somnolence—Methotrexate—breast cancer	2.74e-05	0.000121	CcSEcCtD
Bisoprolol—Dizziness—Capecitabine—breast cancer	2.74e-05	0.000121	CcSEcCtD
Bisoprolol—Dry mouth—Doxorubicin—breast cancer	2.72e-05	0.00012	CcSEcCtD
Bisoprolol—Vomiting—Docetaxel—breast cancer	2.72e-05	0.00012	CcSEcCtD
Bisoprolol—Dyspepsia—Methotrexate—breast cancer	2.71e-05	0.00012	CcSEcCtD
Bisoprolol—Rash—Docetaxel—breast cancer	2.7e-05	0.000119	CcSEcCtD
Bisoprolol—Hypotension—Epirubicin—breast cancer	2.69e-05	0.000119	CcSEcCtD
Bisoprolol—Dermatitis—Docetaxel—breast cancer	2.69e-05	0.000119	CcSEcCtD
Bisoprolol—Confusional state—Doxorubicin—breast cancer	2.69e-05	0.000119	CcSEcCtD
Bisoprolol—Headache—Docetaxel—breast cancer	2.68e-05	0.000118	CcSEcCtD
Bisoprolol—Oedema—Doxorubicin—breast cancer	2.67e-05	0.000118	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Methotrexate—breast cancer	2.66e-05	0.000118	CcSEcCtD
Bisoprolol—Fatigue—Methotrexate—breast cancer	2.66e-05	0.000117	CcSEcCtD
Bisoprolol—Infection—Doxorubicin—breast cancer	2.65e-05	0.000117	CcSEcCtD
Bisoprolol—Pain—Methotrexate—breast cancer	2.63e-05	0.000117	CcSEcCtD
Bisoprolol—Vomiting—Capecitabine—breast cancer	2.63e-05	0.000116	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Epirubicin—breast cancer	2.63e-05	0.000116	CcSEcCtD
Bisoprolol—Shock—Doxorubicin—breast cancer	2.62e-05	0.000116	CcSEcCtD
Bisoprolol—Nervous system disorder—Doxorubicin—breast cancer	2.62e-05	0.000116	CcSEcCtD
Bisoprolol—Thrombocytopenia—Doxorubicin—breast cancer	2.61e-05	0.000116	CcSEcCtD
Bisoprolol—Rash—Capecitabine—breast cancer	2.61e-05	0.000115	CcSEcCtD
Bisoprolol—Insomnia—Epirubicin—breast cancer	2.61e-05	0.000115	CcSEcCtD
Bisoprolol—Dermatitis—Capecitabine—breast cancer	2.61e-05	0.000115	CcSEcCtD
Bisoprolol—Tachycardia—Doxorubicin—breast cancer	2.6e-05	0.000115	CcSEcCtD
Bisoprolol—Headache—Capecitabine—breast cancer	2.59e-05	0.000115	CcSEcCtD
Bisoprolol—Skin disorder—Doxorubicin—breast cancer	2.59e-05	0.000115	CcSEcCtD
Bisoprolol—Paraesthesia—Epirubicin—breast cancer	2.59e-05	0.000115	CcSEcCtD
Bisoprolol—Hyperhidrosis—Doxorubicin—breast cancer	2.58e-05	0.000114	CcSEcCtD
Bisoprolol—Dyspnoea—Epirubicin—breast cancer	2.57e-05	0.000114	CcSEcCtD
Bisoprolol—Somnolence—Epirubicin—breast cancer	2.56e-05	0.000113	CcSEcCtD
Bisoprolol—Nausea—Docetaxel—breast cancer	2.54e-05	0.000112	CcSEcCtD
Bisoprolol—Feeling abnormal—Methotrexate—breast cancer	2.54e-05	0.000112	CcSEcCtD
Bisoprolol—Dyspepsia—Epirubicin—breast cancer	2.54e-05	0.000112	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Methotrexate—breast cancer	2.52e-05	0.000111	CcSEcCtD
Bisoprolol—Hypotension—Doxorubicin—breast cancer	2.49e-05	0.00011	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Epirubicin—breast cancer	2.49e-05	0.00011	CcSEcCtD
Bisoprolol—Fatigue—Epirubicin—breast cancer	2.49e-05	0.00011	CcSEcCtD
Bisoprolol—Pain—Epirubicin—breast cancer	2.47e-05	0.000109	CcSEcCtD
Bisoprolol—Constipation—Epirubicin—breast cancer	2.47e-05	0.000109	CcSEcCtD
Bisoprolol—Nausea—Capecitabine—breast cancer	2.46e-05	0.000109	CcSEcCtD
Bisoprolol—Urticaria—Methotrexate—breast cancer	2.45e-05	0.000108	CcSEcCtD
Bisoprolol—Abdominal pain—Methotrexate—breast cancer	2.44e-05	0.000108	CcSEcCtD
Bisoprolol—Body temperature increased—Methotrexate—breast cancer	2.44e-05	0.000108	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.43e-05	0.000108	CcSEcCtD
Bisoprolol—Insomnia—Doxorubicin—breast cancer	2.41e-05	0.000107	CcSEcCtD
Bisoprolol—Paraesthesia—Doxorubicin—breast cancer	2.4e-05	0.000106	CcSEcCtD
Bisoprolol—Dyspnoea—Doxorubicin—breast cancer	2.38e-05	0.000105	CcSEcCtD
Bisoprolol—Feeling abnormal—Epirubicin—breast cancer	2.38e-05	0.000105	CcSEcCtD
Bisoprolol—Somnolence—Doxorubicin—breast cancer	2.37e-05	0.000105	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Epirubicin—breast cancer	2.36e-05	0.000104	CcSEcCtD
Bisoprolol—Dyspepsia—Doxorubicin—breast cancer	2.35e-05	0.000104	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Doxorubicin—breast cancer	2.3e-05	0.000102	CcSEcCtD
Bisoprolol—Fatigue—Doxorubicin—breast cancer	2.3e-05	0.000102	CcSEcCtD
Bisoprolol—Urticaria—Epirubicin—breast cancer	2.29e-05	0.000101	CcSEcCtD
Bisoprolol—Constipation—Doxorubicin—breast cancer	2.28e-05	0.000101	CcSEcCtD
Bisoprolol—Pain—Doxorubicin—breast cancer	2.28e-05	0.000101	CcSEcCtD
Bisoprolol—Body temperature increased—Epirubicin—breast cancer	2.28e-05	0.000101	CcSEcCtD
Bisoprolol—Abdominal pain—Epirubicin—breast cancer	2.28e-05	0.000101	CcSEcCtD
Bisoprolol—Hypersensitivity—Methotrexate—breast cancer	2.27e-05	0.0001	CcSEcCtD
Bisoprolol—Asthenia—Methotrexate—breast cancer	2.21e-05	9.78e-05	CcSEcCtD
Bisoprolol—Feeling abnormal—Doxorubicin—breast cancer	2.2e-05	9.72e-05	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Doxorubicin—breast cancer	2.18e-05	9.65e-05	CcSEcCtD
Bisoprolol—Pruritus—Methotrexate—breast cancer	2.18e-05	9.64e-05	CcSEcCtD
Bisoprolol—Hypersensitivity—Epirubicin—breast cancer	2.12e-05	9.4e-05	CcSEcCtD
Bisoprolol—Urticaria—Doxorubicin—breast cancer	2.12e-05	9.37e-05	CcSEcCtD
Bisoprolol—Body temperature increased—Doxorubicin—breast cancer	2.11e-05	9.33e-05	CcSEcCtD
Bisoprolol—Abdominal pain—Doxorubicin—breast cancer	2.11e-05	9.33e-05	CcSEcCtD
Bisoprolol—Diarrhoea—Methotrexate—breast cancer	2.11e-05	9.32e-05	CcSEcCtD
Bisoprolol—Asthenia—Epirubicin—breast cancer	2.07e-05	9.15e-05	CcSEcCtD
Bisoprolol—Pruritus—Epirubicin—breast cancer	2.04e-05	9.02e-05	CcSEcCtD
Bisoprolol—Dizziness—Methotrexate—breast cancer	2.04e-05	9.01e-05	CcSEcCtD
Bisoprolol—Diarrhoea—Epirubicin—breast cancer	1.97e-05	8.73e-05	CcSEcCtD
Bisoprolol—Hypersensitivity—Doxorubicin—breast cancer	1.97e-05	8.69e-05	CcSEcCtD
Bisoprolol—Vomiting—Methotrexate—breast cancer	1.96e-05	8.66e-05	CcSEcCtD
Bisoprolol—Rash—Methotrexate—breast cancer	1.94e-05	8.59e-05	CcSEcCtD
Bisoprolol—Dermatitis—Methotrexate—breast cancer	1.94e-05	8.58e-05	CcSEcCtD
Bisoprolol—Headache—Methotrexate—breast cancer	1.93e-05	8.54e-05	CcSEcCtD
Bisoprolol—Asthenia—Doxorubicin—breast cancer	1.91e-05	8.47e-05	CcSEcCtD
Bisoprolol—Dizziness—Epirubicin—breast cancer	1.91e-05	8.43e-05	CcSEcCtD
Bisoprolol—Pruritus—Doxorubicin—breast cancer	1.89e-05	8.35e-05	CcSEcCtD
Bisoprolol—Vomiting—Epirubicin—breast cancer	1.83e-05	8.11e-05	CcSEcCtD
Bisoprolol—Nausea—Methotrexate—breast cancer	1.83e-05	8.09e-05	CcSEcCtD
Bisoprolol—Diarrhoea—Doxorubicin—breast cancer	1.83e-05	8.07e-05	CcSEcCtD
Bisoprolol—Rash—Epirubicin—breast cancer	1.82e-05	8.04e-05	CcSEcCtD
Bisoprolol—Dermatitis—Epirubicin—breast cancer	1.82e-05	8.03e-05	CcSEcCtD
Bisoprolol—Headache—Epirubicin—breast cancer	1.81e-05	7.99e-05	CcSEcCtD
Bisoprolol—Dizziness—Doxorubicin—breast cancer	1.76e-05	7.8e-05	CcSEcCtD
Bisoprolol—Nausea—Epirubicin—breast cancer	1.71e-05	7.58e-05	CcSEcCtD
Bisoprolol—Vomiting—Doxorubicin—breast cancer	1.7e-05	7.5e-05	CcSEcCtD
Bisoprolol—Rash—Doxorubicin—breast cancer	1.68e-05	7.44e-05	CcSEcCtD
Bisoprolol—Dermatitis—Doxorubicin—breast cancer	1.68e-05	7.43e-05	CcSEcCtD
Bisoprolol—Headache—Doxorubicin—breast cancer	1.67e-05	7.39e-05	CcSEcCtD
Bisoprolol—Nausea—Doxorubicin—breast cancer	1.58e-05	7.01e-05	CcSEcCtD
Bisoprolol—ADRB1—GPCR downstream signaling—IL2—breast cancer	7.08e-06	0.000205	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—E2F1—breast cancer	7.03e-06	0.000203	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FGF1—breast cancer	7.03e-06	0.000203	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CSF2—breast cancer	7.03e-06	0.000203	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ABCG2—breast cancer	7.02e-06	0.000203	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CPT1A—breast cancer	7.02e-06	0.000203	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—MTR—breast cancer	7.02e-06	0.000203	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—RAF1—breast cancer	7.01e-06	0.000203	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CB—breast cancer	7e-06	0.000202	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HPSE—breast cancer	6.99e-06	0.000202	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—BRIP1—breast cancer	6.99e-06	0.000202	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—LDHB—breast cancer	6.99e-06	0.000202	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NRG1—breast cancer	6.97e-06	0.000202	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—H2AFX—breast cancer	6.92e-06	0.0002	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—IL2—breast cancer	6.92e-06	0.0002	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—HPGDS—breast cancer	6.89e-06	0.000199	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—E2F1—breast cancer	6.88e-06	0.000199	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—HBA1—breast cancer	6.85e-06	0.000198	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CB—breast cancer	6.84e-06	0.000198	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SPP1—breast cancer	6.75e-06	0.000195	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—CXCL8—breast cancer	6.72e-06	0.000194	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ACHE—breast cancer	6.68e-06	0.000193	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTT1—breast cancer	6.68e-06	0.000193	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ERBB3—breast cancer	6.68e-06	0.000193	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—FGFR2—breast cancer	6.67e-06	0.000193	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HMMR—breast cancer	6.63e-06	0.000192	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA3—breast cancer	6.63e-06	0.000192	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ABCC1—breast cancer	6.63e-06	0.000192	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SPP1—breast cancer	6.61e-06	0.000191	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—CXCL8—breast cancer	6.58e-06	0.00019	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ERBB3—breast cancer	6.53e-06	0.000189	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FGFR2—breast cancer	6.52e-06	0.000189	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—IL2—breast cancer	6.43e-06	0.000186	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PPARGC1B—breast cancer	6.42e-06	0.000186	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TERT—breast cancer	6.4e-06	0.000185	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP17A1—breast cancer	6.32e-06	0.000183	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—IL2—breast cancer	6.29e-06	0.000182	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TERT—breast cancer	6.26e-06	0.000181	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ENO1—breast cancer	6.26e-06	0.000181	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PTGS1—breast cancer	6.26e-06	0.000181	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—FGFR1—breast cancer	6.22e-06	0.00018	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—HIF1A—breast cancer	6.12e-06	0.000177	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FGFR1—breast cancer	6.08e-06	0.000176	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA4—breast cancer	6.06e-06	0.000175	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CA9—breast cancer	6.06e-06	0.000175	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NCOA2—breast cancer	6.03e-06	0.000174	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—HIF1A—breast cancer	5.99e-06	0.000173	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—LEP—breast cancer	5.98e-06	0.000173	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CAV1—breast cancer	5.92e-06	0.000171	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA2—breast cancer	5.91e-06	0.000171	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GPX2—breast cancer	5.91e-06	0.000171	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KDR—breast cancer	5.86e-06	0.000169	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—LEP—breast cancer	5.85e-06	0.000169	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—FASN—breast cancer	5.84e-06	0.000169	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SULT1A1—breast cancer	5.83e-06	0.000169	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GPX4—breast cancer	5.83e-06	0.000169	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—BCHE—breast cancer	5.82e-06	0.000168	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CAV1—breast cancer	5.79e-06	0.000167	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—SLC5A5—breast cancer	5.75e-06	0.000166	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KDR—breast cancer	5.73e-06	0.000166	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ESR1—breast cancer	5.71e-06	0.000165	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA1—breast cancer	5.7e-06	0.000165	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—IDH1—breast cancer	5.7e-06	0.000165	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—FN1—breast cancer	5.64e-06	0.000163	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NAT2—breast cancer	5.63e-06	0.000163	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ESR1—breast cancer	5.58e-06	0.000161	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NFKBIA—breast cancer	5.57e-06	0.000161	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NQO1—breast cancer	5.55e-06	0.000161	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—SLC2A1—breast cancer	5.55e-06	0.000161	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NOTCH1—breast cancer	5.52e-06	0.000159	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FN1—breast cancer	5.51e-06	0.000159	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NFKBIA—breast cancer	5.45e-06	0.000158	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP3A4—breast cancer	5.41e-06	0.000157	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NOTCH1—breast cancer	5.4e-06	0.000156	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KIT—breast cancer	5.39e-06	0.000156	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CG—breast cancer	5.39e-06	0.000156	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—APC—breast cancer	5.39e-06	0.000156	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—EGF—breast cancer	5.33e-06	0.000154	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP1B1—breast cancer	5.32e-06	0.000154	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KIT—breast cancer	5.28e-06	0.000153	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CG—breast cancer	5.28e-06	0.000153	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—APC—breast cancer	5.28e-06	0.000153	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—HSP90AA1—breast cancer	5.22e-06	0.000151	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—EGF—breast cancer	5.22e-06	0.000151	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—MAPK3—breast cancer	5.17e-06	0.000149	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NCOA1—breast cancer	5.08e-06	0.000147	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—BRAF—breast cancer	5.07e-06	0.000147	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—MAPK3—breast cancer	5.05e-06	0.000146	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—STK11—breast cancer	5e-06	0.000145	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP19A1—breast cancer	5e-06	0.000145	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—BRAF—breast cancer	4.96e-06	0.000143	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—MED12—breast cancer	4.94e-06	0.000143	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—DPYD—breast cancer	4.94e-06	0.000143	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IGF1—breast cancer	4.94e-06	0.000143	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—AKT2—breast cancer	4.93e-06	0.000143	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—EGFR—breast cancer	4.91e-06	0.000142	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ALDOA—breast cancer	4.86e-06	0.000141	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IGF1—breast cancer	4.83e-06	0.00014	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—AKT2—breast cancer	4.83e-06	0.00014	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—EGFR—breast cancer	4.81e-06	0.000139	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CD—breast cancer	4.74e-06	0.000137	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NCOA3—breast cancer	4.72e-06	0.000136	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CA—breast cancer	4.7e-06	0.000136	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SERPINE1—breast cancer	4.69e-06	0.000136	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SLC2A2—breast cancer	4.69e-06	0.000136	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—COMT—breast cancer	4.65e-06	0.000135	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—KRAS—breast cancer	4.64e-06	0.000134	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CD—breast cancer	4.64e-06	0.000134	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTP1—breast cancer	4.63e-06	0.000134	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CA—breast cancer	4.59e-06	0.000133	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ABCG2—breast cancer	4.59e-06	0.000133	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CPT1A—breast cancer	4.59e-06	0.000133	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—MTR—breast cancer	4.59e-06	0.000133	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SERPINE1—breast cancer	4.59e-06	0.000133	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—HMOX1—breast cancer	4.57e-06	0.000132	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ITPR1—breast cancer	4.56e-06	0.000132	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—KRAS—breast cancer	4.54e-06	0.000131	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HPGDS—breast cancer	4.5e-06	0.00013	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NOS3—breast cancer	4.48e-06	0.000129	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HBA1—breast cancer	4.48e-06	0.000129	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ABCB1—breast cancer	4.38e-06	0.000127	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NOS3—breast cancer	4.38e-06	0.000127	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTT1—breast cancer	4.37e-06	0.000126	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ACHE—breast cancer	4.37e-06	0.000126	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—TYMS—breast cancer	4.31e-06	0.000124	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CA—breast cancer	4.26e-06	0.000123	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PLA2G4A—breast cancer	4.26e-06	0.000123	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NCOR1—breast cancer	4.26e-06	0.000123	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTM1—breast cancer	4.26e-06	0.000123	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MDM2—breast cancer	4.25e-06	0.000123	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—RAF1—breast cancer	4.23e-06	0.000122	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—RELA—breast cancer	4.21e-06	0.000122	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ERBB2—breast cancer	4.19e-06	0.000121	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CA—breast cancer	4.17e-06	0.000121	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MDM2—breast cancer	4.16e-06	0.00012	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—RAF1—breast cancer	4.14e-06	0.00012	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP17A1—breast cancer	4.13e-06	0.00012	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MTOR—breast cancer	4.13e-06	0.000119	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CB—breast cancer	4.13e-06	0.000119	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—RELA—breast cancer	4.12e-06	0.000119	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ERBB2—breast cancer	4.1e-06	0.000118	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ENO1—breast cancer	4.09e-06	0.000118	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PTGS1—breast cancer	4.09e-06	0.000118	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GPX1—breast cancer	4.08e-06	0.000118	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CB—breast cancer	4.04e-06	0.000117	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MTOR—breast cancer	4.04e-06	0.000117	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP1A1—breast cancer	4.03e-06	0.000117	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP2D6—breast cancer	4.01e-06	0.000116	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ERCC2—breast cancer	4e-06	0.000116	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CXCL8—breast cancer	3.97e-06	0.000115	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—HRAS—breast cancer	3.95e-06	0.000114	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NCOA2—breast cancer	3.94e-06	0.000114	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CXCL8—breast cancer	3.89e-06	0.000112	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CDKN1B—breast cancer	3.88e-06	0.000112	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—HRAS—breast cancer	3.86e-06	0.000112	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—AKT1—breast cancer	3.84e-06	0.000111	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—FASN—breast cancer	3.82e-06	0.00011	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—BCHE—breast cancer	3.81e-06	0.00011	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CASP3—breast cancer	3.8e-06	0.00011	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IL2—breast cancer	3.8e-06	0.00011	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CDKN1B—breast cancer	3.79e-06	0.00011	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—IL6—breast cancer	3.78e-06	0.000109	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—MTHFR—breast cancer	3.76e-06	0.000109	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SLC5A5—breast cancer	3.76e-06	0.000109	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—AKT1—breast cancer	3.75e-06	0.000109	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CASP3—breast cancer	3.72e-06	0.000108	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IL2—breast cancer	3.71e-06	0.000107	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CCND1—breast cancer	3.7e-06	0.000107	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—IL6—breast cancer	3.69e-06	0.000107	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—JUN—breast cancer	3.69e-06	0.000107	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CTNNB1—breast cancer	3.66e-06	0.000106	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NQO1—breast cancer	3.63e-06	0.000105	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SLC2A1—breast cancer	3.63e-06	0.000105	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CCND1—breast cancer	3.62e-06	0.000105	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—JUN—breast cancer	3.61e-06	0.000104	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MMP9—breast cancer	3.59e-06	0.000104	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CTNNB1—breast cancer	3.58e-06	0.000104	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CDKN1A—breast cancer	3.58e-06	0.000103	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PTEN—breast cancer	3.57e-06	0.000103	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MMP9—breast cancer	3.51e-06	0.000102	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CDKN1A—breast cancer	3.5e-06	0.000101	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MAPK8—breast cancer	3.49e-06	0.000101	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PTEN—breast cancer	3.49e-06	0.000101	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—AKT1—breast cancer	3.48e-06	0.000101	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP1B1—breast cancer	3.48e-06	0.000101	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CAV1—breast cancer	3.47e-06	0.0001	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MAPK8—breast cancer	3.42e-06	9.88e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HSP90AA1—breast cancer	3.41e-06	9.87e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—AKT1—breast cancer	3.41e-06	9.85e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NCOA1—breast cancer	3.32e-06	9.6e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SRC—breast cancer	3.31e-06	9.58e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—STK11—breast cancer	3.27e-06	9.46e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP19A1—breast cancer	3.27e-06	9.46e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SRC—breast cancer	3.24e-06	9.37e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—VEGFA—breast cancer	3.23e-06	9.33e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—STAT3—breast cancer	3.19e-06	9.23e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CG—breast cancer	3.16e-06	9.14e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—VEGFA—breast cancer	3.16e-06	9.12e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—STAT3—breast cancer	3.12e-06	9.03e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MAPK3—breast cancer	3.05e-06	8.82e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—COMT—breast cancer	3.04e-06	8.8e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTP1—breast cancer	3.03e-06	8.75e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HMOX1—breast cancer	2.99e-06	8.63e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MAPK3—breast cancer	2.98e-06	8.63e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ITPR1—breast cancer	2.98e-06	8.61e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MYC—breast cancer	2.97e-06	8.58e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TGFB1—breast cancer	2.96e-06	8.56e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MYC—breast cancer	2.9e-06	8.39e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—EGFR—breast cancer	2.9e-06	8.39e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TGFB1—breast cancer	2.9e-06	8.37e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ABCB1—breast cancer	2.87e-06	8.29e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—EGFR—breast cancer	2.84e-06	8.21e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—TYMS—breast cancer	2.81e-06	8.14e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.78e-06	8.04e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NCOR1—breast cancer	2.78e-06	8.04e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTM1—breast cancer	2.78e-06	8.04e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CD—breast cancer	2.78e-06	8.03e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KRAS—breast cancer	2.74e-06	7.93e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ALB—breast cancer	2.74e-06	7.93e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KRAS—breast cancer	2.68e-06	7.76e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GPX1—breast cancer	2.66e-06	7.7e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP1A1—breast cancer	2.64e-06	7.63e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NOS3—breast cancer	2.62e-06	7.58e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ERCC2—breast cancer	2.62e-06	7.56e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CA—breast cancer	2.52e-06	7.28e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CA—breast cancer	2.46e-06	7.13e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—MTHFR—breast cancer	2.46e-06	7.11e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TP53—breast cancer	2.44e-06	7.05e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CB—breast cancer	2.42e-06	7e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PTGS2—breast cancer	2.4e-06	6.94e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TP53—breast cancer	2.38e-06	6.89e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—HRAS—breast cancer	2.33e-06	6.74e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—HRAS—breast cancer	2.28e-06	6.59e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CAV1—breast cancer	2.27e-06	6.56e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IL6—breast cancer	2.23e-06	6.45e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IL6—breast cancer	2.18e-06	6.31e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PTEN—breast cancer	2.09e-06	6.05e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CG—breast cancer	2.07e-06	5.97e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—AKT1—breast cancer	2.06e-06	5.95e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—AKT1—breast cancer	2.01e-06	5.82e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CD—breast cancer	1.82e-06	5.25e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ALB—breast cancer	1.79e-06	5.18e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NOS3—breast cancer	1.72e-06	4.96e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CB—breast cancer	1.58e-06	4.58e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PTGS2—breast cancer	1.57e-06	4.54e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CA—breast cancer	1.48e-06	4.27e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PTEN—breast cancer	1.37e-06	3.96e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—AKT1—breast cancer	1.21e-06	3.49e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CA—breast cancer	9.65e-07	2.79e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—AKT1—breast cancer	7.88e-07	2.28e-05	CbGpPWpGaD
